Skip to main content
Best News Website or Mobile Service
WAN-IFRA Digital Media Awards Worldwide 2022
Best News Website or Mobile Service
Digital Media Awards Worldwide 2022
Hamburger Menu

Advertisement

Advertisement

World

UAE rolls out Sinopharm COVID-19 vaccine to children aged 3-17

UAE rolls out Sinopharm COVID-19 vaccine to children aged 3-17

FILE PHOTO: Doses of the Chinese Sinopharm vaccine against the coronavirus disease (COVID-19) are seen at the Biblioteka kod Milutina restaurant in Kragujevac, Serbia, May 4, 2021. REUTERS/Marko Djurica

DUBAI: The United Arab Emirates will start providing China's Sinopharm COVID-19 vaccine to children aged three to 17, the UAE government said on Twitter on Monday (Aug 2). 

It cited the health ministry as saying the decision comes after clinical trials and extensive evaluations, without providing any details. 

Authorities said in June the trial would monitor the immune response of 900 children.

The Gulf Arab state, which has among the world's highest immunisation rates, was already providing the Pfizer-BioNTech vaccine for children aged 12 to 15.

READ: New Abu Dhabi plant to make COVID-19 vaccine from China's Sinopharm

The health ministry said on Sunday that 78.95 per cent of the UAE population of roughly 9 million had received one vaccine dose while 70.57 per cent had been fully vaccinated.

The UAE, the region's tourism and trade hub, registered 1,519 new coronavirus infections on Sunday to take its total to 682,377 cases and 1,951 deaths. 

It does not provide a breakdown for each of its seven emirates.

It led Phase 3 clinical trials of the vaccine produced by China's state-owned drugmaker Sinopharm and has started manufacturing it under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/ad

Advertisement

Also worth reading

Advertisement